Argenx
ARGX
#575
Rank
A$54.79 B
Marketcap
$916.41
Share price
0.83%
Change (1 day)
23.01%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Cash on Hand

Cash on Hand as of June 2024 : A$4.76 Billion

According to Argenx 's latest financial reports the company has A$4.76 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Argenx - Cash on Hand chart (from 2021 to 2020)

Cash on Hand by year

Year Cash on Hand Change
2022-12-31A$3.22 B-0.04%
2021-12-31A$3.22 B0.93%
2020-12-31A$3.19 B33.01%
2019-12-31A$2.40 B128.95%
2018-12-31A$1.04 B58.1%
2017-12-31A$0.66 B346.87%
2016-12-31A$0.14 B113.73%
2015-12-31A$69.45 M-31.33%
2014-12-31A$0.10 B103.75%
2013-12-31A$49.64 M78.94%
2012-12-31A$27.74 M-28.22%
2011-12-31A$38.64 M181.06%
2010-12-31A$13.75 M